Nateglinide Side Effects

For the Consumer

Applies to nateglinide: oral tablet

Along with its needed effects, nateglinide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking nateglinide:

Less Common

• Convulsions (seizures)
• unconsciousness

Check with your doctor as soon as possible if any of the following side effects occur while taking nateglinide:

Less Common

• Low blood sugar, including anxious feeling, behavior change similar to being drunk, blurred vision, cold sweats, confusion, cool pale skin, difficulty in thinking, drowsiness, excessive hunger, fast heartbeat, headache, nausea, nervousness, nightmares, restless sleep, shakiness, slurred speech, or unusual tiredness or weakness

Incidence not known-occurred during clinical practice

• Hives or welts
• itching
• redness of skin
• skin rash

Some side effects of nateglinide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

• Cough
• runny or stuffy nose
• sore throat

Less Common

• Abdominal or stomach pain
• back pain
• chills
• dizziness
• pain in joints or muscles
• sneezing
• swelling in joints

For Healthcare Professionals

Applies to nateglinide: oral tablet

General

The most frequently reported adverse events included upper respiratory tract infections and symptoms of hypoglycemia.^[Ref]

Metabolic

Common (1% to 10%): Hypoglycemia

Frequency not reported: Increases in mean uric acid level^[Ref]

Hypoglycemia has been reported and has generally been mild and corrected by intake of carbohydrates. In comparative clinical trials, hypoglycemia was reported in 10.4%, 14.5%, 6.9%, 19.8%, and 4.1% in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, and placebo, respectively.

Mean uric acid levels were increased in patient receiving this drug as monotherapy. The difference from placebo in treated patients was 0.29 mg/dL, 0.45 mg/dL, 0.28 mg/dL, and 0.19 mg/dL in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, respectively. The clinical significance of these findings is unknown.^[Ref]

Respiratory

Common (1% to 10%): Upper respiratory tract infection, bronchitis, coughing^[Ref]

Hypersensitivity

Postmarketing reports: Hypersensitivity reactions such as rash, itching, and urticaria^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, abdominal pain, dyspepsia, nausea

Uncommon (0.1% to 1%): Vomiting^[Ref]

Gastrointestinal symptoms, especially diarrhea and nausea, were no more common in patients using this drug in combination with metformin than in patients receiving metformin alone.^[Ref]

Hepatic

Postmarketing reports: Elevated liver enzymes, jaundice, cholestatic hepatitis^[Ref]

Nervous system

Common (1% to 10%): Dizziness^[Ref]

Musculoskeletal

Common (1% to 10%): Back pain, arthropathy^[Ref]

Cardiovascular

Peripheral edema was no more common in patients using this drug in combination with rosiglitazone than in patients receiving rosiglitazone alone.^[Ref]

Frequency not reported: Peripheral edema^[Ref]

Dermatologic

Postmarketing reports: Erythema multiforme^[Ref]

Immunologic

Common (1% to 10%): Flu symptoms^[Ref]

Other

Common (1% to 10%): Accidental trauma^[Ref]

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer